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Clinical PerspectiveWhat Is New?Extended follow‐up and large population are important to assess the role of diabetes mellitus (DM) in left main coronary artery (LMCA) disease.In LMCA disease with DM, percutaneous coronary intervention showed comparable rates of mortality and serious composite outcome at 10 years.Unlikely in the bare‐metal stent era, in which there was a significant interaction between DM status and revascularization method on mortality and serious composite outcome, no interaction was observed between diabetic status and treatment in the drug‐eluting stent era.What Are the Clinical Implications?Even though DM was related to higher 10‐year mortality and composite outcome in patients with LMCA disease after myocardial revascularization, its role to guide clinical decision making regarding the choice of coronary revascularization strategy is limited in LMCA disease.In the drug‐eluting stent era, percutaneous coronary intervention would be a reasonable option for myocardial revascularization in patients with LMCA disease, even in those with DM. Decision making between percutaneous coronary intervention and coronary artery bypass grafting in patients with LMCA disease should take into consideration several clinical or anatomic aspects and patient preference.

 {#jah34987-sec-0009}

Nonstandard Abbreviations and Acronyms**BMS** bare‐metal stent**CABG** coronary artery bypass grafting**CAD** coronary artery disease**DES** drug‐eluting stent**DM** diabetes mellitusIPTW inverse probability of treatment weighting**LMCA** left main coronary artery**MAIN‐COMPARE** Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization**MI** myocardial infarction**PCI** percutaneous coronary intervention**SYNTAX** Synergy Between PCI With Taxus and Cardiac Surgery**TVR** target‐vessel revascularization

Introduction {#jah34987-sec-0010}
============

As compared with patients without diabetes mellitus (DM), patients with DM usually have more diffuse and complex anatomic features of coronary artery disease (CAD), which is associated with high morbidity and mortality.[1](#jah34987-bib-0001){ref-type="ref"} Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are recommended for revascularization treatments for patients with DM with obstructive CAD.[2](#jah34987-bib-0002){ref-type="ref"} In particular, CABG has been considered to be the preferred revascularization strategy in patients with DM and multivessel or complex CAD.[3](#jah34987-bib-0003){ref-type="ref"}, [4](#jah34987-bib-0004){ref-type="ref"}, [5](#jah34987-bib-0005){ref-type="ref"}, [6](#jah34987-bib-0006){ref-type="ref"}

Among various anatomic subtypes of atherosclerotic CAD, the optimal choice of revascularization strategies is more crucial for patients with left main coronary artery (LMCA) disease because of the large amount of myocardium at risk. The current US and European guidelines recommend that most patients with LMCA disease undergo CABG.[7](#jah34987-bib-0007){ref-type="ref"}, [8](#jah34987-bib-0008){ref-type="ref"} However, the updated evidence supports that PCI is a safe and effective modality for patients with LMCA disease and low‐to‐intermediate anatomic complexity as compared with CABG,[6](#jah34987-bib-0006){ref-type="ref"}, [9](#jah34987-bib-0009){ref-type="ref"}, [10](#jah34987-bib-0010){ref-type="ref"} although some trials show conflicting results, supporting better effect with CABG over PCI.[11](#jah34987-bib-0011){ref-type="ref"} Until recently, data were limited regarding the influence of DM on the relative outcomes after PCI or CABG and on decision making of particular revascularization strategies in patients with LMCA disease. In addition, given that the effects of DM and myocardial revascularization on mortality and major cardiovascular events is not fully revealed within a limited follow‐up duration, longer‐term evaluation of 5 to 10 years is essential to better define differences in outcomes between PCI and CABG.

We therefore sought to determine differences in very long‐term (10‐year) comparative outcomes between PCI and CABG according to the presence of DM using data from the extended follow‐up of the MAIN‐COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry.[12](#jah34987-bib-0012){ref-type="ref"}

Methods {#jah34987-sec-0011}
=======

Data Sources {#jah34987-sec-0012}
------------

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study Design and Population {#jah34987-sec-0013}
---------------------------

The study population consisted of 2240 consecutive patients with unprotected LMCA disease who underwent PCI (n=1102) or CABG (n=1138) between January 2000 and June 2006 at 12 major cardiac centers in Korea, within the MAIN‐COMPARE registry. The design, inclusion criteria, and primary results of the MAIN‐COMPARE study have been published previously.[12](#jah34987-bib-0012){ref-type="ref"}, [13](#jah34987-bib-0013){ref-type="ref"}, [14](#jah34987-bib-0014){ref-type="ref"} Patients who had prior bypass surgery, those who underwent concomitant valvular or aortic surgery, and those who had an ST‐segment--elevation myocardial infarction (MI), or presented with cardiogenic shock were excluded.

The choice of treatment strategy between PCI and CABG was at the discretion of the attending cardiologists or cardiac surgeons with careful consideration of clinical risk factors, anatomic complexity, patient preference, and surgical risk. All procedures and surgery were guided by standard techniques and management. Because of device availability, PCI was performed exclusively with bare‐metal stents (BMSs) between January 2000 and May 2003 and exclusively with DESs between May 2003 and June 2006. Antiplatelet therapy and periprocedural anticoagulation were performed in accordance with the accepted guidelines. During follow‐up, patient management including medical treatment was performed in accordance with accepted guidelines and established standards of care. This study was approved by the local ethics committee of each hospital, and all patients provided written informed consent for the use of their clinical data for the registry study.

Study Outcomes and Follow‐Up {#jah34987-sec-0014}
----------------------------

The end points of the study were death; a composite of death, Q‐wave MI, or stroke; and target‐vessel revascularization (TVR). Death was defined as death from any cause. Q‐wave MI was defined as documentation of a new pathological Q‐wave after the index revascularization. Stroke was defined as a focal neurological deficit of central origin lasting \>24 hours, confirmed by a neurologist and imaging. TVR was defined as any percutaneous or surgical revascularization of the treated vessel, including any segments of the left anterior descending artery and/or left circumflex artery. All clinical events were confirmed by source documentation collected at each hospital and centrally adjudicated by an independent group of clinicians.

Clinical follow‐up was recommended at 1 month, 6 months, 1 year, and annually thereafter. In the 10‐year MAIN‐COMPARE study, the follow‐up period was extended through December 31, 2016, to ensure that all patients had the opportunity to be followed up for at least 10 years. Complete information on vital status and date of death were obtained through December 31, 2016, from the National Population Registry of the Korea National Statistical Office on the basis of the unique 13‐digit personal identification number that all Korean citizens have. The detailed methods for data acquisition and management during extended follow‐up have been reported elsewhere.[12](#jah34987-bib-0012){ref-type="ref"}

Statistical Analysis {#jah34987-sec-0015}
--------------------

Continuous variables were presented as mean±SD and compared using the Student *t* test or Mann--Whitney *U* test. Categorical variables were presented as counts (percentages) and compared using the chi‐square or Fisher exact test, as appropriate. Event rates were estimated on Kaplan--Meier estimates in time‐to‐first‐event analyses and were compared using the log‐rank test.

Outcomes of patients who received PCI versus CABG were evaluated, stratified by the presence of medically treated DM. Crude and adjusted risks for adverse outcomes were compared by univariate and multivariable Cox proportional hazards regression analyses. Multiple regression analyses using Cox proportional hazard models were performed with CABG group as the reference category and with PCI group as the indicator variable. Variables with *P* values of ≤0.1 and clinically relevant covariates irrespective of their statistical relevance in univariate analyses were candidates for inclusion in multivariate Cox proportional hazards models. The final models were determined by backward elimination. When left ventricular ejection fraction was included in the multivariable model, multiple imputation with m=10 was performed, and the results of the Cox regression analyses on 10 imputed data sets were combined using Rubin\'s rules.

Inverse probability of treatment weighting (IPTW) based on the propensity score (probability of receiving PCI) was used as the primary tool to adjust for differences in the baseline characteristics between the PCI and CABG groups.[15](#jah34987-bib-0015){ref-type="ref"} IPTW gives different weights to patients based on their characteristics, to create a "virtual" data set that mimics the data that would have been observed if the treatment was randomly assigned. To handle the missingness of left ventricular ejection fraction in 18.5% of the patients, we used the missingness pattern approach. That is, we fitted the separate propensity score model for the patients with complete data and those with missing left ventricular ejection fraction. The propensity score was estimated using a nonparsimonious logistic regression model, with the PCI group as the dependent variable and all the baseline characteristics outlined in Table [1](#jah34987-tbl-0001){ref-type="table"} as covariates. Once each patient\'s propensity score was estimated, stabilized weights were calculated using the method described in the previous literature.[16](#jah34987-bib-0016){ref-type="ref"} We examined the similarity of the baseline characteristics between the treatment groups before and after IPTW.[17](#jah34987-bib-0017){ref-type="ref"} After confirming the comparability of the 2 groups in the data with IPTW, we ran the Cox proportional hazard model and made statistical inference using robust standard errors (Huber sandwich estimator).[18](#jah34987-bib-0018){ref-type="ref"}

###### 

Baseline Characteristics of the Patients

<table><thead><tr class="header"><th>Characteristics</th><th>Overall (n=2240)</th><th><em>P</em> Value</th><th>Diabetes Mellitus (n=722)</th><th><em>P</em> Value</th><th>No Diabetes Mellitus (n=1518)</th><th><em>P</em> Value</th><th></th><th></th><th></th></tr></thead><tbody><tr class="odd"><td>Age, y</td><td>61.3±11.7</td><td>62.9±9.4</td><td>&lt;0.001</td><td>63.5±10.0</td><td>63.6±8.7</td><td>0.87</td><td>60.4±12.2</td><td>62.6±9.8</td><td>&lt;0.001</td></tr><tr class="even"><td>Male</td><td>779 (70.7)</td><td>830 (72.9)</td><td>0.26</td><td>228 (69.7)</td><td>294 (74.4)</td><td>0.19</td><td>551 (71.1)</td><td>536 (72.1)</td><td>0.69</td></tr><tr class="odd"><td>Treatment of diabetes mellitus</td><td></td><td></td><td></td><td></td><td></td><td>0.85</td><td></td><td></td><td></td></tr><tr class="even"><td>Required insulin</td><td></td><td></td><td></td><td>75 (22.9)</td><td>93 (23.5)</td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>Required OHA</td><td></td><td></td><td></td><td>252 (77.1)</td><td>302 (76.5)</td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Wave</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td></tr><tr class="odd"><td><p>Wave 1</p><p>BMS vs Concurrent CABG</p></td><td>318 (28.9)</td><td>448 (39.4)</td><td></td><td>76 (23.2)</td><td>139 (35.2)</td><td></td><td>242 (31.2)</td><td>309 (41.6)</td><td></td></tr><tr class="even"><td><p>Wave 2</p><p>DES vs Concurrent CABG</p></td><td>784 (71.1)</td><td>690 (60.6)</td><td></td><td>251 (76.8)</td><td>256 (64.8)</td><td></td><td>553 (68.8)</td><td>434 (58.4)</td><td></td></tr><tr class="odd"><td>Hypertension</td><td>546 (49.5)</td><td>562 (49.4)</td><td>0.97</td><td>197 (60.2)</td><td>228 (57.7)</td><td>0.54</td><td>349 (45.0)</td><td>334 (45.0)</td><td>&gt;0.99</td></tr><tr class="even"><td>Hyperlipidemia</td><td>315 (28.6)</td><td>371 (32.6)</td><td>0.044</td><td>110 (33.6)</td><td>139 (35.2)</td><td>0.72</td><td>205 (26.5)</td><td>232 (31.2)</td><td>0.046</td></tr><tr class="odd"><td>Current smoker</td><td>282 (25.6)</td><td>339 (29.8)</td><td>0.030</td><td>72 (22.0)</td><td>107 (27.1)</td><td>0.14</td><td>210 (27.1)</td><td>232 (31.2)</td><td>0.09</td></tr><tr class="even"><td>Prior MI</td><td>89 (8.1)</td><td>132 (11.6)</td><td>0.006</td><td>32 (9.8)</td><td>55 (13.9)</td><td>0.11</td><td>57 (7.4)</td><td>77 (10.4)</td><td>0.048</td></tr><tr class="odd"><td>Prior PCI</td><td>200 (18.1)</td><td>125 (11.0)</td><td>&lt;0.001</td><td>80 (24.5)</td><td>50 (12.7)</td><td>&lt;0.001</td><td>120 (15.5)</td><td>75 (10.1)</td><td>0.002</td></tr><tr class="even"><td>Congestive heart failure</td><td>27 (2.5)</td><td>38 (3.3)</td><td>0.21</td><td>14 (4.3)</td><td>23 (5.8)</td><td>0.35</td><td>13 (1.7)</td><td>15 (2.0)</td><td>0.62</td></tr><tr class="odd"><td>Prior stroke</td><td>78 (7.1)</td><td>83 (7.3)</td><td>0.91</td><td>33 (10.1)</td><td>38 (9.6)</td><td>0.93</td><td>45 (5.8)</td><td>45 (6.1)</td><td>0.92</td></tr><tr class="even"><td>Peripheral vascular disease</td><td>16 (1.5)</td><td>62 (5.4)</td><td>&lt;0.001</td><td>4 (1.2)</td><td>33 (8.4)</td><td>&lt;0.001</td><td>12 (1.5)</td><td>29 (3.9)</td><td>0.008</td></tr><tr class="odd"><td>Chronic kidney disease</td><td>30 (2.7)</td><td>34 (3.0)</td><td>0.80</td><td>17 (5.2)</td><td>26 (6.6)</td><td>0.53</td><td>13 (1.7)</td><td>8 (1.1)</td><td>0.43</td></tr><tr class="even"><td>Clinical indication</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>0.001</td><td></td><td></td><td>&lt;0.001</td></tr><tr class="odd"><td>Silent ischemia</td><td>33 (3.0)</td><td>25 (2.2)</td><td></td><td>13 (4.0)</td><td>11 (2.8)</td><td></td><td>20 (2.6)</td><td>14 (1.9)</td><td></td></tr><tr class="even"><td>Chronic stable angina</td><td>353 (32.0)</td><td>226 (19.9)</td><td></td><td>97 (29.7)</td><td>72 (18.2)</td><td></td><td>256 (33.0)</td><td>154 (20.7)</td><td></td></tr><tr class="odd"><td>Unstable angina</td><td>608 (55.2)</td><td>775 (68.1)</td><td></td><td>173 (52.9)</td><td>266 (67.3)</td><td></td><td>435 (56.1)</td><td>509 (68.5)</td><td></td></tr><tr class="even"><td>NSTEMI</td><td>108 (9.8)</td><td>112 (9.8)</td><td></td><td>44 (13.5)</td><td>46 (11.6)</td><td></td><td>64 (8.3)</td><td>66 (8.9)</td><td></td></tr><tr class="odd"><td>Acute coronary syndrome</td><td>716 (65.0)</td><td>887 (77.9)</td><td>&lt;0.001</td><td>217 (66.4)</td><td>312 (79.0)</td><td>&lt;0.001</td><td>499 (64.4)</td><td>575 (77.4)</td><td>&lt;0.001</td></tr><tr class="even"><td>LVEF, %</td><td>60.6±10.8</td><td>57.2±11.9</td><td>&lt;0.001</td><td>58.8±11.9</td><td>55.6±13.0</td><td>0.002</td><td>61.3±10.2</td><td>58.0±11.2</td><td>&lt;0.001</td></tr><tr class="odd"><td>SYNTAX score (n=1580)</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td></tr><tr class="even"><td>0–22</td><td>408 (49.8)</td><td>100 (13.1)</td><td></td><td>94 (37.8)</td><td>25 (9.6)</td><td></td><td>314 (55.1)</td><td>75 (15.0)</td><td></td></tr><tr class="odd"><td>23–32</td><td>225 (27.5)</td><td>164 (21.6)</td><td></td><td>75 (30.1)</td><td>52 (19.9)</td><td></td><td>150 (26.3)</td><td>112 (22.4)</td><td></td></tr><tr class="even"><td>≥33</td><td>186 (22.7)</td><td>497 (65.3)</td><td></td><td>80 (32.1)</td><td>184 (70.5)</td><td></td><td>106 (18.6)</td><td>313 (62.6)</td><td></td></tr><tr class="odd"><td>Involved location</td><td></td><td></td><td>0.045</td><td></td><td></td><td>0.21</td><td></td><td></td><td>0.17</td></tr><tr class="even"><td>Ostium and/or midshaft</td><td>557 (50.5)</td><td>526 (46.2)</td><td></td><td>157 (48.0)</td><td>170 (43.0)</td><td></td><td>400 (51.6)</td><td>356 (47.9)</td><td></td></tr><tr class="odd"><td>Distal bifurcation</td><td>545 (49.5)</td><td>612 (53.8)</td><td></td><td>170 (52.0)</td><td>225 (57.0)</td><td></td><td>375 (48.4)</td><td>387 (52.1)</td><td></td></tr><tr class="even"><td>Disease extent</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td><td></td><td></td><td>&lt;0.001</td></tr><tr class="odd"><td>LM only</td><td>278 (25.2)</td><td>71 (6.2)</td><td></td><td>56 (17.1)</td><td>13 (3.3)</td><td></td><td>222 (28.6)</td><td>58 (7.8)</td><td></td></tr><tr class="even"><td>LM+single‐vessel disease</td><td>264 (24.0)</td><td>119 (10.5)</td><td></td><td>73 (22.3)</td><td>30 (7.6)</td><td></td><td>191 (24.6)</td><td>89 (12.0)</td><td></td></tr><tr class="odd"><td>LM+double‐vessel disease</td><td>287 (26.0)</td><td>299 (26.3)</td><td></td><td>102 (31.2)</td><td>92 (23.3)</td><td></td><td>185 (23.9)</td><td>207 (27.9)</td><td></td></tr><tr class="even"><td>LM+triple‐vessel disease</td><td>273 (24.8)</td><td>649 (57.0)</td><td></td><td>96 (29.4)</td><td>260 (65.8)</td><td></td><td>177 (22.8)</td><td>389 (52.4)</td><td></td></tr><tr class="odd"><td>Restenotic lesion</td><td>32 (2.9)</td><td>14 (1.2)</td><td>0.008</td><td>10 (3.1)</td><td>3 (0.8)</td><td>0.042</td><td>22 (2.8)</td><td>11 (1.5)</td><td>0.10</td></tr></tbody></table>

Values are presented as n (%) or mean±SD. BMS indicates bare‐metal stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stent; LM, left main; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; OHA, oral hypoglycemic agent; PCI, percutaneous coronary intervention; and SYNTAX, Synergy Between PCI With TAXUS and Cardiac Surgery.

For all crude, multivariable‐adjusted, and IPTW analyses, treatment effects were evaluated in all the patients and in each group of patients with and without DM. To test the statistical significance of the difference in treatment effect of revascularization methods between the patients with and without DM, the interaction term between diabetic status and the treatment method was included in the multivariate and weighted Cox models using the IPTW method that were built on the basis of the data from all the patients. As described previously,[12](#jah34987-bib-0012){ref-type="ref"} these analyses were performed in the overall cohort, wave 1 cohort of the BMS era (BMS versus concurrent CABG between January 2000 and May 2003), and wave 2 cohort of the DES era (DES versus concurrent CABG between May 2003 and June 2006). As the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score was available only for a subset of patients (n=1580; 70.5%), we performed sensitivity analyses in the group with the baseline SYNTAX score. All reported *P* values were 2‐sided, and *P*\<0.05 were considered statistically significant. R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses.

Results {#jah34987-sec-0016}
=======

Baseline Characteristics {#jah34987-sec-0017}
------------------------

Detailed information on procedural characteristics of patients in the MAIN‐COMPARE registry have been described previously[13](#jah34987-bib-0013){ref-type="ref"}: (1) the mean number of stents implanted in LMCA lesions and per patient was 1.2±0.5 and 1.9±1.1, respectively; (2) mean total length and mean stent diameter was 28.0±20.7 and 3.5±0.4 mm, respectively; (3) among CABG patients, 42% underwent off‐pump surgery; and (4) 98% underwent revascularization of the left anterior descending artery with an arterial conduit; and (5) mean number of grafts used was 2.9±1.0 (2.2±0.9 arterial grafts and 0.7±0.8 venous grafts).

Among 2240 patients with LMCA disease treated with PCI (n=1102) or CABG (n=1138), 722 (32.2%) had medically treated DM. As expected, compared with patients without DM, patients without DM had higher risks of clinical and anatomic risk‐factor profiles and had higher 10‐year incidence rates of clinical outcomes (Table [S1](#jah34987-sup-0001){ref-type="supplementary-material"} and Figure [S1](#jah34987-sup-0001){ref-type="supplementary-material"}). Of the patients with DM, 327 (45.3%) received PCI and 395 (54.7%) underwent CABG. Of the 1518 patients without DM, 775 (51.1%) received PCI and 743 (48.9%) underwent CABG.

The baseline demographic, clinical, and angiographic characteristics of the patients who underwent PCI and CABG in the overall population and in the group with or without DM are shown in Table [1](#jah34987-tbl-0001){ref-type="table"}. In general, compared with the patients who received PCI, those who underwent CABG had a significantly greater prevalence of comorbidities (old age, hyperlipidemia, prior MI, peripheral vascular disease, unstable angina, and lower ejection fraction) and a higher proportion of SYNTAX scores of ≥33, distal bifurcation involvement, and LMCA plus triple‐vessel disease. This pattern was similar in the group with or without DM. These baseline characteristics in the BMS era (wave 1 cohort) and DES era (wave 2 cohort) are shown in Tables [S2](#jah34987-sup-0001){ref-type="supplementary-material"} and [S3](#jah34987-sup-0001){ref-type="supplementary-material"}. Compared with the patients enrolled in the wave 1 period, those enrolled in the wave 2 period had higher‐risk clinical and anatomic characteristics.

Ten‐Year Clinical Outcomes {#jah34987-sec-0018}
--------------------------

The median follow‐up duration among all the patients was 12.0 years (interquartile interval, 10.7--13.5 years). The observed rates of clinical outcomes after PCI and CABG in the overall group and in the group with or without DM at 10 years are shown in Table [2](#jah34987-tbl-0002){ref-type="table"} and Figure [1](#jah34987-fig-0001){ref-type="fig"}. The 10‐year rates of all‐cause mortality and the composite of death, Q‐wave MI, or stroke were not significantly different between PCI and CABG in either of the cohorts with and without . The TVR rates were lower after CABG than after PCI in the patients both with and without DM. These findings were unchanged after multivariable and IPTW adjustment for differences in baseline characteristics (Table [2](#jah34987-tbl-0002){ref-type="table"} and Figure [2](#jah34987-fig-0002){ref-type="fig"}). No significant interactions were found between diabetes mellitus status and treatment method in any of the adjusted 10‐year risks of study outcomes (*P* ~interaction~=0.41 for mortality, *P* ~interaction~=0.40 for composite outcome, and *P* ~interaction~=0.82 for TVR).

###### 

10‐Year Rates and Hazard Ratios for Clinical Outcomes[a](#jah34987-note-0006){ref-type="fn"}

  Outcomes                      Event Rates at 10‐Year (n/%)   Crude        Multivariate Adjusted[b](#jah34987-note-0007){ref-type="fn"}   IPTW Adjusted                                                                      
  ----------------------------- ------------------------------ ------------ -------------------------------------------------------------- --------------- ------------------- --------- ------ ------------------- --------- ------
  Overall patients                                                                                                                                                                                                            
  Death                         229 (21.0)                     259 (22.9)   0.91 (0.78--1.06)                                              0.23            1.00 (0.82--1.22)   0.99      0.42   1.06 (0.84--1.35)   0.61      0.41
  Death, Q‐wave MI, or stroke   257 (23.6)                     295 (26.1)   0.89 (0.77--1.03)                                              0.12            0.99 (0.82--1.19)   0.91      0.42   1.06 (0.86--1.32)   0.58      0.40
  TVR                           219 (21.1)                     62 (6.0)     3.85 (2.95--5.02)                                              \<0.001         4.71 (3.31--6.71)   \<0.001   0.95   5.05 (3.42--7.45)   \<0.001   0.82
  Patients with DM                                                                                                                                                                                                            
  Death                         95 (29.4)                      113 (28.8)   1.01 (0.80--1.29)                                              0.92            1.08 (0.85--1.38)   0.54             1.23 (0.92--1.65)   0.17      
  Death, Q‐wave MI, or stroke   100 (30.9)                     126 (32.1)   0.97 (0.77--1.23)                                              0.81            1.25 (0.97--1.61)   0.09             1.23 (0.93--1.62)   0.16      
  TVR                           72 (24.5)                      24 (6.9)     3.97 (2.58--6.10)                                              \<0.001         4.07 (2.65--6.26)   \<0.001          4.86 (3.04--7.78)   \<0.001   
  Patients without DM                                                                                                                                                                                                         
  Death                         134 (17.5)                     146 (19.8)   0.89 (0.73--1.08)                                              0.24            1.03 (0.84--1.27)   0.75             1.07 (0.85--1.36)   0.57      
  Death, Q‐wave MI, or stroke   157 (20.5)                     169 (22.9)   0.88 (0.73--1.06)                                              0.17            1.00 (0.82--1.20)   0.97             1.07 (0.86--1.33)   0.55      
  TVR                           147 (19.9)                     38 (5.5)     3.88 (2.77--5.44)                                              \<0.001         4.50 (3.16--6.41)   \<0.001          4.97 (3.37--7.32)   \<0.001   

CABG indicates coronary artery bypass grafting; DM, diabetes mellitus; HR, hazard ratio; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TVR, target‐vessel revascularization.

Event rates were derived from the Kaplan--Meier estimates. Hazard ratio is the risk of PCI for clinical outcomes compared with that of CABG.

Multivariate models were adjusted for age, sex, wave, diabetes mellitus, cerebrovascular disease, peripheral vascular disease, chronic renal failure, left ventricular ejection fraction, clinical presentation, involved location of the left main coronary artery, and extent of disease.

![Kaplan--Meier curves for 10‐year outcomes after PCI or CABG in patients with or without DM.\
The left panel (**A** through **C**) shows cumulative event curves for patients with DM and the right panel (**D** through **F**) showed event curves for patients without DM. The upper panel (**A** and **D**) indicates all‐cause death, the middle panel (**B** and **E**) indicates a composite of death, Q‐wave MI, or stroke; and the lower panel (**C** and **F**) indicates target‐vessel revascularization. CABG indicates coronary artery bypass grafting; DM, diabetes mellitus; MI, myocardial infarction; non‐DM, non--diabetes mellitus; and PCI, percutaneous coronary intervention.](JAH3-9-e015372-g001){#jah34987-fig-0001}

![Adjusted event curves for 10‐year outcomes after PCI or CABG in patients with or without DM using inverse probability weighting.\*\
The left panel (**A** through **C**) shows cumulative event curves for patients with DM, and the right panel (**D** through **F**) shows event curves for patients without DM. The upper panel (**A** and **D**) indicates all‐cause death, the middle panel (**B** and **E**) indicates a composite of death, Q‐wave MI, or stroke; and the lower panel (**C** and **F**) indicates target‐vessel revascularization. \*Inverse probability of treatment weighting gives different weights to patients based on their characteristics, to create a "virtual" data set that mimics the data that would have been observed if the treatment was randomly assigned. This figure was drawn with individuals after weighting to study population. The adjusted survival curves were estimated with the use of the inverse‐probability‐weighting approach of Cole and Hernan.[33](#jah34987-bib-0033){ref-type="ref"} aHR indicates adjusted hazard ratio; CABG, coronary artery bypass grafting; DM, diabetes mellitus; MI, myocardial infarction; non‐DM, non--diabetes mellitus; and PCI, percutaneous coronary intervention.](JAH3-9-e015372-g002){#jah34987-fig-0002}

The results of the analyses stratified by stent type are shown in Table [3](#jah34987-tbl-0003){ref-type="table"}. In the wave 1 cohort of BMS and concurrent CABG, patients with DM fared nominally better with CABG than with PCI with respect to the adjusted risks of death and composite outcome, and vice versa for patients without DM (Figure [3](#jah34987-fig-0003){ref-type="fig"}). Significant interaction was present between DM status and revascularization type for composite outcome of death, Q‐wave MI, or stroke (*P* ~interaction~=0.04), and a nonsignificant trend was observed for mortality (*P* ~interaction~=0.09). In the wave 2 cohort of DES and concurrent CABG, these differential outcomes according to DM status, favoring CABG in patients with DM, has diminished without significant interactions (*P* ~interaction~=0.63 for mortality and 0.47 for composite outcome; Figure [4](#jah34987-fig-0004){ref-type="fig"}).

###### 

10‐Year Rates and Hazard Ratios for Clinical Outcomes Stratified by Stent Type[a](#jah34987-note-0009){ref-type="fn"}

  Outcomes                          Event Rates at 10‐Year (n/%)   Crude        IPTW Adjusted                                                
  --------------------------------- ------------------------------ ------------ ------------------- --------- -------------------- --------- ------
  Wave 1 (BMS vs concurrent CABG)                                                                                                            
  Overall patients                                                                                                                           
  Death                             59 (18.6)                      103 (23.2)   0.72 (0.55--0.94)   0.014     0.78 (0.54--1.13)    0.19      0.09
  Death, Q‐wave MI, or stroke       65 (20.5)                      118 (26.5)   0.68 (0.53--0.88)   0.003     0.74 (0.52--1.05)    0.09      0.04
  TVR                               65 (21.3)                      29 (7.1)     3.28 (2.19--4.91)   \<0.001   4.98 (2.92--8.50)    \<0.001   0.23
  Patients with DM                                                                                                                           
  Death                             20 (26.7)                      36 (26.1)    0.88 (0.56--1.38)   0.57      1.34 (0.79--2.26)    0.28      
  Death, Q‐wave MI, or stroke       22 (29.4)                      41 (29.7)    0.85 (0.55--1.32)   0.48      1.38 (0.85--2.23)    0.19      
  TVR                               14 (20.8)                      11 (8.7)     2.78 (1.36--5.68)   0.005     2.98 (1.35--6.56)    0.007     
  Patients without DM                                                                                                                        
  Death                             39 (16.1)                      67 (21.8)    0.68 (0.49--0.94)   0.02      0.79 (0.54--1.14)    0.21      
  Death, Q‐wave MI, or stroke       43 (17.8)                      77 (25.1)    0.64 (0.47--0.87)   0.004     0.74 (0.52--1.06)    0.10      
  TVR                               51 (21.6)                      18 (6.4)     3.60 (2.20--5.90)   \<0.001   4.91 (2.90--8.31)    \<0.001   
  Wave 2 (DES vs concurrent CABG)                                                                                                            
  Overall patients                                                                                                                           
  Death                             170 (21.9)                     156 (22.8)   1.02 (0.84--1.23)   0.87      1.32 (0.96--1.82)    0.08      0.63
  Death, Q‐wave MI, or stroke       192 (24.8)                     177 (25.9)   1.01 (0.84--1.22)   0.89      1.37 (1.02--1.83)    0.036     0.47
  TVR                               154 (21.1)                     33 (5.3)     4.43 (3.09--6.35)   \<0.001   5.09 (2.93--8.84)    \<0.001   0.55
  Patients without DM                                                                                                                        
  Death                             75 (30.2)                      77 (30.3)    1.04 (0.78--1.38)   0.81      1.17 (0.82--1.66)    0.39      
  Death, Q‐wave MI, or stroke       78 (31.4)                      85 (33.4)    1.00 (0.76--1.32)   0.98      1.14 (0.81--1.61)    0.44      
  TVR                               58 (25.5)                      13 (5.9)     4.85 (2.76--8.51)   \<0.001   6.68 (3.69--12.08)   \<0.001   
  Patients without DM                                                                                                                        
  Death                             95 (18.1)                      78 (18.4)    1.06 (0.81--1.38)   0.68      1.33 (0.97--1.84)    0.08      
  Death, Q‐wave MI, or stroke       114 (21.7)                     92 (21.4)    1.07 (0.84--1.36)   0.60      1.38 (1.03--1.85)    0.03      
  TVR                               96 (9.1)                       20 (5.0)     4.31 (2.70--6.89)   \<0.001   5.03 (2.90--8.71)    \<0.001   

BMS indicates bare‐metal stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stents; DM, diabetes mellitus; HR, hazard ratio; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TVR, target‐vessel revascularization.

Event rates were derived from the Kaplan--Meier estimates. Hazard ratio is the risk of PCI for clinical outcomes compared with CABG.

![Adjusted event curves for 10‐year outcomes after BMS or concurrent CABG in Patients with or without DM using inverse probability weighting.\
The left panel (**A** through **C**) shows cumulative event curves for patients with DM, and the right panel (**D** through **F**) shows event curves for patients without DM. The upper panel (**A** and **D**) indicates all‐cause death; the middle panel (**B** and **E**) indicates a composite of death, Q‐wave MI, or stroke; and the lower panel (**C** and **F**) indicates target‐vessel revascularization. aHR indicates adjusted hazard ratio; CABG, coronary artery bypass grafting; DM, diabetes mellitus; MI, myocardial infarction; non‐DM, non--diabetes mellitus; and PCI, percutaneous coronary intervention.](JAH3-9-e015372-g003){#jah34987-fig-0003}

![Adjusted event curves for 10‐year outcomes after DES or concurrent CABG in patients with or without DM using inverse probability weighting.\
The left panel (**A** through **C**) shows cumulative event curves for patients with DM, and the right panel (**D** through **F**) shows event curves for patients without DM. The upper panel (**A** and **D**) indicates all‐cause death; the middle panel (**B** and **E**) indicates a composite of death, Q‐wave MI, or stroke; and the lower panel (**C** and **F**) indicates target‐vessel revascularization. aHR indicates adjusted hazard ratio; BMS, bare‐metal stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stent; DM, diabetes mellitus; MI, myocardial infarction; and non‐DM, non--diabetes mellitus; and PCI, percutaneous coronary intervention.](JAH3-9-e015372-g004){#jah34987-fig-0004}

Sensitivity Analysis in the Patients With Baseline SYNTAX Scores {#jah34987-sec-0019}
----------------------------------------------------------------

Of the 2240 patients enrolled in the registry, 1580 (70.5%) had a baseline SYNTAX score, which were measured retrospectively by a core laboratory. The 10‐year clinical outcomes in this subcohort and in each group stratified by stent type are shown in Tables [S4](#jah34987-sup-0001){ref-type="supplementary-material"}, [S5](#jah34987-sup-0001){ref-type="supplementary-material"}, and Figure [S2](#jah34987-sup-0001){ref-type="supplementary-material"}. These sensitivity analyses revealed consistent findings with the relative effect of PCI and CABG according to DM status, in which the interaction effect of DM was more prominent. In the BMS era, statistically significant interactions were present between diabetic status and revascularization type for the adjusted 10‐year rates of mortality (*P* ~interaction~=0.007) and composite outcome (*P* ~interaction~\<0.001; Figure [S3](#jah34987-sup-0001){ref-type="supplementary-material"}). By contrast, this interaction effect of DM and revascularization type on the outcomes was absent in the DES era (Figure [S4](#jah34987-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34987-sec-0020}
==========

The major findings from the present analysis, which is the longest follow‐up study to date that evaluates the relative treatment effects of PCI and CABG for LMCA revascularization stratified by the presence of DM, are as follows: (1) compared with patients without DM, patients with DM had a nearly 1.5‐fold higher risk of death and the composite outcome of death, Q‐wave MI, or stroke at 10 years; (2) overall, there was no significant difference in the adjusted 10‐year risks of mortality and serious composite outcome after PCI or CABG in patients both with and without DM, but the risk of TVR was consistently higher after PCI; (3) a significant interaction was present between DM status and treatment with BMS compared with CABG in the 10‐year risks of mortality and composite outcome, favoring CABG in patients with DM; and (4) no interaction was found between DM status and treatment with DES compared with CABG for the 10‐year clinical outcomes.

Several studies have found that patients with DM are more likely to have more complex and multivessel CAD, with a more diffuse and aggressive form of atherosclerosis.[1](#jah34987-bib-0001){ref-type="ref"}, [19](#jah34987-bib-0019){ref-type="ref"} Thus, among several important clinical risk factors, DM has been regarded as a major determinant for predicting worse clinical outcomes and has a pivotal role for the choice of optimal coronary revascularization.[20](#jah34987-bib-0020){ref-type="ref"}, [21](#jah34987-bib-0021){ref-type="ref"} However, the follow‐up durations of prior studies were still too short to establish the full effect of the revascularization method on survival and hard clinical end point, particularly considering the diverging or converging Kaplan--Meier curves in specific subgroups. In addition, the detriment effect of DM on major cardiovascular events or mortality might be particularly noticeable with longer follow‐up duration. In this regard, the main strength of this study was that we evaluated whether there were clinically relevant differences in long‐term outcomes beyond 10 years after PCI or CABG according to DM status. Thus, our study may provide important clinical insights for the selection of the most effective therapy for this high‐risk subset of patients with DM and LMCA disease.

The key findings of the present study do not support the role of DM as an important modifier for the comparative effect of PCI and CABG for LMCA disease. To evaluate the clinical usefulness of important risk factors, we should consider not only their prognostic ability to predict the future risk of adverse events, but also their discriminating capacity to better guide decision making between PCI and CABG.[22](#jah34987-bib-0022){ref-type="ref"} As expected, in our study, DM was an important predictor of adverse events after LMCA revascularization. However, the role of specific risk factors for optimal decision making should be considered in the context of the interaction effect, as they guide decision making between PCI and CABG.[23](#jah34987-bib-0023){ref-type="ref"} If a significant interaction is present, the clinical or anatomic factor aids decision making between CABG and PCI. In a recent pooled analysis of individual patient data, the presence of DM was reported to have a significant interaction effect for 5‐year mortality favoring CABG over PCI in patients with multivessel CAD (*P* ~interaction~=0.045), but not in those with LMCA disease (*P* ~interaction~=0.13).[6](#jah34987-bib-0006){ref-type="ref"} These findings also confirmed the impact of DM with respect to the primary composite end point (*P* ~interaction~=0.82) and mortality (*P* ~interaction~=0.22) in the subgroup analysis of the EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial with low‐to‐intermediate SYNTAX scores.[24](#jah34987-bib-0024){ref-type="ref"} Consistent with such findings, in our extended follow‐up study, DM had no significant interaction effect with PCI and CABG for LMCA revascularization in establishing 10‐year clinical outcomes. However, a recent 5‐year report of the EXCEL trial showed a late catch‐up of primary end point and an increased risk of mortality with a contemporary DES as compared with CABG.[25](#jah34987-bib-0025){ref-type="ref"} Further study is required to determine the impact of DM on comparative outcomes during the extended follow‐up.

By contrast, DM was still an important effect modifier in patients with multivessel disease and the benefit of CABG over PCI was shown in patients with multivessel CAD and DM. The extended follow‐up (≈8 years) report of the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease) trial shows that CABG leads to lower all‐cause mortality than PCI in patients with DM with multivessel disease.[26](#jah34987-bib-0026){ref-type="ref"} A recently published SYNTAX study[27](#jah34987-bib-0027){ref-type="ref"} also showed that CABG provided a significant survival benefit in patients with 3‐vessel disease but not in patients with LMCA disease at 10 years. Similarly, the discrepancy between impact of DM on LMCA disease versus multivessel disease has been found in coronary revascularization with PCI or CABG. The benefit of CABG in patients with DM might be attributed to complete revascularization in more diffuse and complex multivessel CAD.[28](#jah34987-bib-0028){ref-type="ref"}, [29](#jah34987-bib-0029){ref-type="ref"}, [30](#jah34987-bib-0030){ref-type="ref"}

The relative benefits of CABG versus PCI with stents in terms of outcomes are highly debated, particularly each time stent design is enhanced. Our study population included both the BMS and DES eras, so we could demonstrate the secular change of DM impact on comparative outcomes after PCI or CABG for LMCA disease. In the BMS era, a comparison of PCI with BMS and concurrent CABG found a significant interaction between DM and revascularization type for 10‐year clinical outcomes, in which CABG had an advantage over PCI with respect to mortality and serious composite outcomes in DM patients. This pattern was much more prominent after full adjustment of detailed information on angiographic complexity in the patient cohort with baseline SYNTAX scores. By contrast, moving on to the DES era, DM did not appear to modify the treatment effects of PCI and CABG for LMCA disease. Given that improvements in stent design have led to inclusion of higher‐risk patients with more complex disease and also this higher‐risk profile is already reflected in the contemporary clinical practice, these findings may be more clinically relevant and applicable. Notably, the clinical usefulness of DM as an important decision‐making factor for a specific treatment option was not obvious in recent trials that compared CABG and PCI with DES for LMCA revascularization.[22](#jah34987-bib-0022){ref-type="ref"} The remarkable improvements in stent platform and technology, procedural technique and experience, and adjunctive pharmacology have narrowed the treatment gap in favor of CABG over PCI for patients with DM.[31](#jah34987-bib-0031){ref-type="ref"} In addition, the advanced and rapidly evolving optimal medical therapy (ie, high‐potency statins, newer P2Y12 inhibitors, and more aggressive blood pressure targets) and DM management probably attenuate the treatment gap between CABG and PCI.[32](#jah34987-bib-0032){ref-type="ref"}

Our study has several limitations. First, this was a nonrandomized, observational registry study with inherent methodological limitations; thus, its overall findings must be considered hypothetical and hypothesis generating only. Second, because the treatment choice was left to the physician or patient, our findings are subject to selection bias. Although propensity‐score analyses were performed to adjust for potential selection bias, the unmeasured confounders might have affected the results. Third, owing to the relatively limited number of patients, this study is not sufficiently powered to compare between insulin‐treated and non--insulin‐treated DM and comparative outcomes after PCI and CABG. Fourth, the SYNTAX score was not available in 29.5% of patients. Therefore, our findings should be further evaluated through extended follow‐up of the EXCEL and NOBLE (Nordic‐Baltic‐British Left Main Revascularization Study) trials using contemporary DES.

Conclusions {#jah34987-sec-0021}
===========

In conclusion, in this longest‐term follow‐up study of patients with LMCA disease, the 10‐year rates of mortality and serious composite outcome of death, Q‐wave MI, or stroke were similar between PCI and CABG in patients with or without DM. However, we observed the differential effect of DM on comparative outcomes of PCI and CABG over time from the BMS to the DES era. These findings may suggest that the presence of DM should not penalize the specific revascularization strategy for LMCA disease in the heart‐team discussion for optimal decision making in contemporary clinical practice.
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